Curcumin and Berberine Arrest Maturation and Activation of Dendritic CellsDerived from Lupus Erythematosus Patients

Current Molecular Pharmacology · Published 2024-01-29 · DOI 10.2174/0118761429249908231221080806

Authors being retrieved — see the publisher record. https://doi.org/10.2174/0118761429249908231221080806

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Clinical Efficacy Observation of Acupuncture at Zusanli and Yanglingquan Points as Adjuvant Therapy to Antibiotics for Acute Calculous Cholecystitis (ACC) · Acupuncture and Electro-Therapeutics Research · 2026 · Cites or is cited by this article
• Targeting fPRDM16 to restore collagen phagocytosis: A mechanism to counteract the persistent fibrosis in aging lungs · Current Molecular Pharmacology · 2026 · Same journal
• Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer · Current Molecular Pharmacology · 2025 · Same journal
• Protective Effect of Platycodin D on Allergic Rhinitis in Mice through DPP4/JAK2/STAT3 Pathway Inhibition · Current Molecular Pharmacology · 2025 · Same journal
• Neuroprotective Potential of Tanshinone-IIA in Mitigating Propionic Acidinduced Experimental Autism-like Behavioral and Neurochemical Alterations: Insights into c-JNK and p38MAPK Pathways · Current Molecular Pharmacology · 2024 · Same journal
• Regulatory Mechanisms of STAT3 in GBM and its Impact on TMZ Resistance · Current Molecular Pharmacology · 2025 · Same journal
• Optimization of bioinformatics-designed thiazolide derivatives as SARS-CoV-2 nucleocapsid protein inhibitors · Current Molecular Pharmacology · 2026 · Same journal
• Doxazosin Attenuates Development of Testosterone Propionate-induced Prostate Growth by regulating TGF-β/Smad Signaling Pathway, Prostate-specific Antigen Expression and Reversing Epithelial-Mesenchymal Transition in Mice and Stroma Cells · Current Molecular Pharmacology · 2025 · Same journal
• Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma · Current Molecular Pharmacology · 2025 · Same journal
• IGFBP1 is a potential monitoring biomarker of disease activity in elderly patients with inflammatory bowel disease · Current Molecular Pharmacology · 2026 · Same journal